Modulation of Thrombosis Significantly Reduces Testicular Damage after Testicular Torsion in Rats: Anti-Thrombotic Treatment and Testicular Torsion

Urology. 2016 Feb:88:227.e1-7. doi: 10.1016/j.urology.2015.11.004. Epub 2015 Nov 11.

Abstract

Objective: To evaluate the effects of thrombolysis and/or anticoagulation on testicular viability after testicular tortion (TT) was the aim of this study. It has been suggested that alterations of circulation during TT result in thrombus formation that might prevent sufficient perfusion after detorsion. Due to the narrow safety margin of testicular perfusion, even moderate disturbances in blood supply can cause major testicular damage.

Methods: In 112 rats, the right testicle was torsed for 3 or 6 hours. After detorsion and randomization, they received either enoxaparin, alteplase, both, or placebo, according to their subgroup. Thrombus formation was accessed via D-dimers, pDNA, oxidative testicular damage was evaluated via glutathione peroxidase and malondialdehyde, and cellular damage via inhibin B, testosterone, histological analysis (Johnsen score, Cosetino grading), and TUNEL assay.

Results: One hundred and twelve rats were included in the study. The treatment with alteplase or enoxaparin showed significantly less testicular damage and significantly improved Sertoli cell function. Enoxaparin significantly reduced oxidative impairment.

Conclusion: The results of the study indicate that TT induces thrombus formation and demonstrate that modulation of thrombosis significantly ameliorates testicular damage in rats. Hence, this treatment option after TT ought to be evaluated in humans.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticoagulants / therapeutic use*
  • Enoxaparin / therapeutic use*
  • Fibrinolytic Agents / therapeutic use*
  • Male
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Spermatic Cord Torsion / complications
  • Spermatic Cord Torsion / therapy*
  • Testis / blood supply*
  • Thrombosis / etiology
  • Thrombosis / therapy*
  • Tissue Plasminogen Activator / therapeutic use*

Substances

  • Anticoagulants
  • Enoxaparin
  • Fibrinolytic Agents
  • Tissue Plasminogen Activator